Avita Medical Inc Stock Price, News & Analysis

AVITA Medical (NASDAQ: RCEL) has successfully completed a private placement in Australia, raising approximately US$15 million (A$23 million) through the issuance of 17.2 million new CHESS Depositary Interests (CDIs). The placement was priced at A$1.32 per CDI, representing an 11% discount to the last closing price of A$1.48.

The funds will be utilized for working capital requirements and strategic flexibility to support the company's therapeutic acute wound portfolio growth. AVITA Medical expects this capital to sustain operations until it achieves free cash flow in 2026. The new CDIs are scheduled for settlement on August 19, 2025, with trading on the ASX commencing August 20, 2025.

AVITA Medical (NASDAQ: RCEL) has announced an upcoming investor webinar briefing scheduled for August 14, 2025, at 9 AM AEDT (August 13 at 4 PM PST). The presentation will feature CEO Jim Corbett and CFO David O'Toole, who will discuss the company's Q2 2025 financial and business results.

The webinar will include a Q&A session, with participants able to submit questions through the registration page. A replay will be made available on AVITA Medical's investor relations website after the event.

AVITA Medical (NASDAQ: RCEL) reported Q2 2025 financial results with commercial revenue of $18.4 million, up 21% year-over-year, despite facing significant headwinds. The company reported a net loss of $9.9 million ($0.38 per share), an improvement from $15.4 million loss in Q2 2024.

Key developments include Medicare Administrative Contractor (MAC) payment delays affecting RECELL® System demand, leading to revised full-year 2025 revenue guidance of $76-81 million, down from $100-106 million. The company amended credit terms with OrbiMed, lowering revenue covenants and issuing stock instead of cash payment.

Clinical highlights show RECELL reducing hospital stays by 36%, and CMS approval of New Technology Add-on Payment for trauma wounds. The company now expects to reach cash flow break-even in Q2 2026 and GAAP profitability in Q3 2026.

AVITA Medical (NASDAQ: RCEL) has announced significant changes to its Board of Directors. Dr. Michael Tarnoff, MD, FACS has been appointed as a non-executive Director effective August 6, 2025, bringing extensive executive and medical leadership experience from Tufts Medical Center and Medtronic.

Additionally, the company announced a leadership transition where Cary Vance will succeed Lou Panaccio as Board Chair effective August 7, 2025. Panaccio steps down after more than 10 years of service. The changes come as AVITA Medical strengthens its focus on advancing patient-centric wound-healing technologies and expanding its presence across healthcare settings.

AVITA Medical (NASDAQ: RCEL) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close. The company will host a conference call and webcast on the same day at 1:30 p.m. Pacific Time (August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time).

Investors can access the live webcast through the Events & Presentations section on AVITA Medical's website. To join via telephone, participants must pre-register to receive dial-in details and a personal PIN. A replay will be available on the company's Investor Relations website after the event.

AVITA Medical (NASDAQ: RCEL) presented groundbreaking data at the British Burn Association Annual Meeting showcasing significant benefits of their RECELL technology for burn patients. The largest real-world analysis to date, examining over 6,300 patients from 2019-2024, revealed that RECELL's Spray-On Skin Cells reduced hospital stays by 6.2 days (35.7%) compared to traditional split-thickness autografts for burns covering less than 30% total body surface area. This resulted in approximately $300 million in cost savings over the study period. RECELL, now used in more than 130 U.S. burn centers, requires less donor skin than traditional grafting and offers benefits including reduced pain, faster healing, and fewer procedures. The technology creates an autologous cell suspension from a small sample of the patient's own skin to support wound healing.

AVITA Medical announced the first clinical publication of Cohealyx, their collagen-based dermal matrix, in the Journal of Surgery. The study demonstrated significantly faster wound bed vascularization and autograft readiness compared to conventional methods, achieving results in 5-10 days versus the typical 2-4 weeks. In a case series at Ohio State University Wexner Medical Center, two patients with complex hand wounds showed excellent outcomes, with one patient achieving vascularization by day 5 and autografting by day 7, while the second patient reached vascularization by day 10 and autografting by day 13. Cohealyx, developed using proprietary TetraPure Technology, contains crosslinked collagen types I and III, supporting optimal cellular migration and rapid revascularization. The accelerated timeline could improve clinical outcomes by enabling earlier wound closure and reducing patient complications.

AVITA Medical's RECELL platform, including RECELL GO, has won the 'Best New Technology Solution – Surgical' award at the 2025 MedTech Breakthrough Awards. The FDA-approved RECELL technology, used for treating thermal burn wounds and full-thickness skin defects, has successfully treated over 30,000 patients worldwide. The platform's key advantages include requiring less donor skin than traditional grafting, reducing donor-site pain, and accelerating recovery. RECELL GO enhances procedural consistency and surgical team coordination while maintaining physician centrality. The technology has demonstrated improved outcomes including fewer procedures, better functional and aesthetic results, and reduced hospital stays. The recognition came among 4,500 global nominations, with AVITA's SVP Dr. Katie Bush also receiving the 2025 Emerald Pinnacle Healthcare Award in the Medical Device category.

AVITA Medical (NASDAQ: RCEL) is hosting its virtual Acute Wound Care Showcase 2025 on May 13, 2025, at 11:00 a.m. Pacific Time. The event will feature presentations from leading burn and trauma clinicians using AVITA's technologies, alongside patient testimonials about their treatment experiences with the company's solutions.

CEO Jim Corbett and SVP of Scientific and Medical Affairs Dr. Katie Bush will present AVITA's integrated approach to acute wound care, highlighting key technologies including RECELL®, Cohealyx™, and PermeaDerm®. The showcase will include a live Q&A session, with registration available through the company's website. A replay will be accessible from May 14 on AVITA Medical's Investor Relations site.